Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43353
UPID:
RIPK2_HUMAN
Alternative names:
CARD-containing interleukin-1 beta-converting enzyme-associated kinase; RIP-like-interacting CLARP kinase; Receptor-interacting protein 2; Tyrosine-protein kinase RIPK2
Alternative UPACC:
O43353; B7Z748; Q6UWF0
Background:
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2), with alternative names such as CARD-containing interleukin-1 beta-converting enzyme-associated kinase and Tyrosine-protein kinase RIPK2, plays a pivotal role in immune responses. It acts as a crucial effector in NOD1 and NOD2 signaling pathways, leading to the activation of NF-kappa-B, a key transcription factor in immune response, growth control, and apoptosis protection.
Therapeutic significance:
Understanding the role of Receptor-interacting serine/threonine-protein kinase 2 could open doors to potential therapeutic strategies.